Arthur Christopoulos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9308507/publications.pdf

Version: 2024-02-01

356	30,208	5248	6630
papers	citations	83 h-index	156 g-index

395	395	395	22166
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Positive allosteric modulation of endogenous delta opioid receptor signaling in the enteric nervous system is a potential treatment for gastrointestinal motility disorders. American Journal of Physiology - Renal Physiology, 2022, 322, G66-G78.	1.6	7
2	Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation. Nature Communications, 2022, 13, 92.	5.8	30
3	Secretin amino-terminal structure-activity relationships and complementary mutagenesis at the site of docking to the secretin receptor. Molecular Pharmacology, 2022, , MOLPHARM-AR-2022-000502.	1.0	0
4	A structural basis for amylin receptor phenotype. Science, 2022, 375, eabm9609.	6.0	28
5	Biased Profile of Xanomeline at the Recombinant Human M₄ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2022, 13, 1206-1218.	1.7	6
6	Structural Features of Iperoxoâ€“BQCA Muscarinic Acetylcholine Receptor Hybrid Ligands Determining Subtype Selectivity and Efficacy. ACS Chemical Neuroscience, 2022, 13, 97-111.	1.7	4
7	Investigating Drivers for M ₁ Muscarinic Acetylcholine Receptorâ€Mediated Adverse Events by M ₁ Positive Allosteric Modulators. FASEB Journal, 2022, 36, .	0.2	0
8	P598. Exploring the Molecular Determinants for Functional Selectivity of the Antipsychotic Xanomeline at Muscarinic Acetylcholine Receptors. Biological Psychiatry, 2022, 91, S331.	0.7	0
9	Development of Novel 4â€Arylpyridinâ€2â€one and 6â€Arylpyrimidinâ€4â€one Positive Allosteric Modulators of the M 1 Muscarinic Acetylcholine Receptor. ChemMedChem, 2021, 16, 216-233.	1.6	4
10	Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. Frontiers in Pharmacology, 2021, 12, 628060.	1.6	5
11	A robust method for particulate detection of a genetic tag for 3D electron microscopy. ELife, 2021, 10, .	2.8	16
12	Structure and dynamics of the CGRP receptor in apo and peptide-bound forms. Science, 2021, 372, .	6.0	57
13	Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. PLoS Biology, 2021, 19, e3001295.	2.6	41
14	Acetylcholine receptors (muscarinic) in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
15	Identification of a Novel Allosteric Site at the M5 Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2021, 12, 3112-3123.	1.7	6
16	Acetylcholine receptors (muscarinic) in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
17	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. British Journal of Pharmacology, 2021, 178, S1-S26.	2.7	183
18	Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia. Nature, 2021, 597, 571-576.	13.7	84

#	Article	IF	Citations
19	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	2.7	337
20	Neurological, neuropsychiatric and neurodevelopmental complications of COVID-19. Australian and New Zealand Journal of Psychiatry, 2021, 55, 750-762.	1.3	35
21	Cognitive behavioral markers of neurodevelopmental trajectories in rodents. Translational Psychiatry, 2021, 11, 556.	2.4	4
22	From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimerâ€™s disease. Cell, 2021, 184, 5886-5901.e22.	13.5	44
23	Defining and unpacking the core concepts of pharmacology education. Pharmacology Research and Perspectives, 2021, 9, e00894.	1.1	14
24	Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms. BMJ Open Diabetes Research and Care, 2021, 9, e002285.	1.2	6
25	Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol. Frontiers in Endocrinology, 2021, 12, 789957.	1.5	3
26	Activation of the GLP-1 receptor by a non-peptidic agonist. Nature, 2020, 577, 432-436.	13.7	119
27	Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 465-483.	2.3	23
28	Evaluation of Operational Models of Agonism and Allosterism at Receptors with Multiple Orthosteric Binding Sites. Molecular Pharmacology, 2020, 97, 35-45.	1.0	17
29	Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Molecular Cell, 2020, 80, 485-500.e7.	4.5	111
30	Restoring Agonist Function at a Chemogenetically Modified M₁ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2020, 11, 4270-4279.	1.7	1
31	Structure and dynamics of the active Gs-coupled human secretin receptor. Nature Communications, 2020, 11, 4137.	5.8	46
32	Probe dependence and biased potentiation of metabotropic glutamate receptor 5 is mediated by differential ligand interactions in the common allosteric binding site. Biochemical Pharmacology, 2020, 177, 114013.	2.0	7
33	Structure and Dynamics of Adrenomedullin Receptors AM₁ and AM₂ Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins. ACS Pharmacology and Translational Science, 2020, 3, 263-284.	2.5	71
34	Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. Biological Psychiatry, 2020, 88, 898-909.	0.7	24
35	Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nature Chemical Biology, 2020, 16, 240-249.	3.9	36
36	Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation. Molecular Cell, 2020, 77, 656-668.e5.	4.5	92

#	Article	IF	Citations
37	Rational development of a high-affinity secretin receptor antagonist. Biochemical Pharmacology, 2020, 177, 113929.	2.0	7
38	Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias. Frontiers in Pharmacology, 2020, 11, 606656.	1.6	30
39	Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism. Biochemical Pharmacology, 2020, 177, 114011.	2.0	7
40	Sustainable Pharmacy Education in the Time of COVID-19. American Journal of Pharmaceutical Education, 2020, 84, ajpe8088.	0.7	84
41	Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D₂ Receptor. Journal of Medicinal Chemistry, 2019, 62, 371-377.	2.9	17
42	Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nature Communications, 2019, 10, 3289.	5.8	47
43	Molecular Determinants of the Intrinsic Efficacy of the Antipsychotic Aripiprazole. ACS Chemical Biology, 2019, 14, 1780-1792.	1.6	19
44	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	2.7	519
45	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. British Journal of Pharmacology, 2019, 176, S1-S20.	2.7	295
46	Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor. Molecular Pharmacology, 2019, 95, 245-259.	1.0	5
47	Deconvoluting the Molecular Control of Binding and Signaling at the Amylin 3 Receptor: RAMP3 Alters Signal Propagation through Extracellular Loops of the Calcitonin Receptor. ACS Pharmacology and Translational Science, 2019, 2, 183-197.	2.5	8
48	Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology. Neuropharmacology, 2019, 149, 83-96.	2.0	17
49	Crystal structure of the M ₅ muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26001-26007.	3.3	48
50	6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M₁ mAChR: The Determinants of Allosteric Activity. ACS Chemical Neuroscience, 2019, 10, 1099-1114.	1.7	7
51	The Molecular Control of Calcitonin Receptor Signaling. ACS Pharmacology and Translational Science, 2019, 2, 31-51.	2.5	38
52	Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. Neuropharmacology, 2019, 144, 244-255.	2.0	22
53	Acetylcholine receptors (muscarinic) (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
54	Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptorâ€“Gs complex. Nature, 2018, 555, 121-125.	13.7	263

#	Article	IF	Citations
55	Discovery and Optimization of Potent and CNS Penetrant M₅-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. ACS Chemical Neuroscience, 2018, 9, 1572-1581.	1.7	13
56	New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. British Journal of Pharmacology, 2018, 175, 4036-4046.	2.7	49
57	Structureâ€“Activity Relationships of Pan-GÎ±_{q/11} Coupled Muscarinic Acetylcholine Receptor Positive Allosteric Modulators. ACS Chemical Neuroscience, 2018, 9, 1818-1828.	1.7	7
58	A Structureâ€“Activity Relationship Study of Bitopic N⁶-Substituted Adenosine Derivatives as Biased Adenosine A₁ Receptor Agonists. Journal of Medicinal Chemistry, 2018, 61, 2087-2103.	2.9	29
59	Correspondence: Reply to â€˜Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injuryâ€™. Nature Communications, 2018, 9, 530.	5.8	6
60	Structure-based discovery of selective positive allosteric modulators of antagonists for the M ₂ muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2419-E2428.	3.3	57
61	Muscarinic M5 receptors modulate ethanol seeking in rats. Neuropsychopharmacology, 2018, 43, 1510-1517.	2.8	33
62	To Bind or Not to Bind: Unravelling GPCR Polypharmacology. Cell, 2018, 172, 636-638.	13.5	20
63	The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions. Scientific Reports, 2018, 8, 1208.	1.6	16
64	Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms. Biochemical Pharmacology, 2018, 148, 111-129.	2.0	19
65	The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D 2 receptor. Biochemical Pharmacology, 2018, 148, 315-328.	2.0	26
66	Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism. Journal of Biological Chemistry, 2018, 293, 9370-9387.	1.6	43
67	Identification of Global and Ligand-Specific Calcium Sensing Receptor Activation Mechanisms. Molecular Pharmacology, 2018, 93, 619-630.	1.0	20
68	Bitopic Binding Mode of an M₁ Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. Molecular Pharmacology, 2018, 93, 645-656.	1.0	25
69	Divergent effects of strontium and calciumâ€sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity. British Journal of Pharmacology, 2018, 175, 4095-4108.	2.7	29
70	Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M₁ Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2018, 94, 770-783.	1.0	10
71	Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M₁ Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles. Journal of Medicinal Chemistry, 2018, 61, 2875-2894.	2.9	14
72	Recent advances in the determination of G protein-coupled receptor structures. Current Opinion in Structural Biology, 2018, 51, 28-34.	2.6	51

#	Article	IF	Citations
73	Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. Biochemical Pharmacology, 2018, 150, 214-244.	2.0	24
74	Structural Basis for Binding of Allosteric Drug Leads in the Adenosine A1 Receptor. Scientific Reports, 2018, 8, 16836.	1.6	63
75	Utility of an â€œAllosteric Site-Impairedâ€•M₂Muscarinic Acetylcholine Receptor as a Novel Construct for Validating Mechanisms of Action of Synthetic and Putative Endogenous Allosteric Modulators. Molecular Pharmacology, 2018, 94, 1298-1309.	1.0	3
76	Dual Action Calcium-Sensing Receptor Modulator Unmasks Novel Mode-Switching Mechanism. ACS Pharmacology and Translational Science, 2018, 1, 96-109.	2.5	13
77	Rules of Engagement: GPCRs and G Proteins. ACS Pharmacology and Translational Science, 2018, 1, 73-83.	2.5	93
78	Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists. Biochemical Pharmacology, 2018, 156, 406-419.	2.0	45
79	Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature, 2018, 561, 492-497.	13.7	210
80	Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors. Journal of General Physiology, 2018, 150, 1360-1372.	0.9	38
81	Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1. Biochemical Pharmacology, 2018, 156, 223-240.	2.0	6
82	Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor. Biochemical Pharmacology, 2018, 154, 243-254.	2.0	19
83	Structural insights into G-protein-coupled receptor allostery. Nature, 2018, 559, 45-53.	13.7	255
84	DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo. ACS Pharmacology and Translational Science, 2018, 1, 61-72.	2.5	143
85	Dominant Negative G Proteins Enhance Formation and Purification of Agonist-GPCR-G Protein Complexes for Structure Determination. ACS Pharmacology and Translational Science, 2018, 1, 12-20.	2.5	96
86	Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nature Reviews Molecular Cell Biology, 2018, 19, 638-653.	16.1	457
87	Strength in numbersâ€”an arrestin interaction code. Nature Structural and Molecular Biology, 2018, 25, 437-439.	3.6	0
88	Structure of the adenosine-bound human adenosine A1 receptorâ€“Gi complex. Nature, 2018, 558, 559-563.	13.7	274
89	The International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR): Relevance to pharmacology today and challenges for the future. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-8-10.	0.0	0
90	Adenosine G Proteinâ€Coupled Receptor Biased Agonism to Treat Ischemic Heart Disease. FASEB Journal, 2018, 32, 555.19.	0.2	0

#	Article	IF	Citations
91	Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. Chemical Reviews, 2017, 117, 111-138.	23.0	91
92	Isoform-Specific Biased Agonism of Histamine H₃Receptor Agonists. Molecular Pharmacology, 2017, 91, 87-99.	1.0	21
93	Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity. Cell, 2017, 168, 867-877.e13.	13.5	237
94	Phase-plate cryo-EM structure of a class B GPCRâ€“G-protein complex. Nature, 2017, 546, 118-123.	13.7	424
95	Capadenoson, a clinically trialed partial adenosine A 1 receptor agonist, can stimulate adenosine A 2B receptor biased agonism. Biochemical Pharmacology, 2017, 135, 79-89.	2.0	37
96	High throughput, quantitative analysis of human osteoclast differentiation and activity. Analytical Biochemistry, 2017, 519, 51-56.	1.1	7
97	Structure-Based Design and Discovery of New M₂ Receptor Agonists. Journal of Medicinal Chemistry, 2017, 60, 9239-9250.	2.9	19
98	Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nature Communications, 2017, 8, 14232.	5.8	104
99	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G proteinâ€coupled receptors. British Journal of Pharmacology, 2017, 174, S17-S129.	2.7	557
100	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology, 2017, 174, S1-S16.	2.7	269
101	A kinetic view of GPCR allostery and biased agonism. Nature Chemical Biology, 2017, 13, 929-937.	3.9	126
102	Allosteric modulation as a unifying mechanism for receptor function and regulation. Diabetes, Obesity and Metabolism, 2017, 19, 4-21.	2.2	41
103	Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery. Neuropharmacology, 2017, 115, 60-72.	2.0	43
104	Structural features embedded in G protein-coupled receptor co-crystal structures are key to their success in virtual screening. PLoS ONE, 2017, 12, e0174719.	1.1	11
105	Improving virtual screening of G protein-coupled receptors via ligand-directed modeling. PLoS Computational Biology, 2017, 13, e1005819.	1.5	8
106	Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy. Molecular Pharmacology, 2016, 90, 703-714.	1.0	53
107	Role of the Second Extracellular Loop of the Adenosine A₁ Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity. Molecular Pharmacology, 2016, 90, 715-725.	1.0	56
108	Novel Irreversible Agonists Acting at the A₁ Adenosine Receptor. Journal of Medicinal Chemistry, 2016, 59, 11182-11194.	2.9	20

#	Article	IF	Citations
109	Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators. ACS Chemical Biology, 2016, 11, 1870-1879.	1.6	26
110	Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5675-84.	3.3	82
111	The complexity of signalling mediated by the glucagon-like peptide-1 receptor. Biochemical Society Transactions, 2016, 44, 582-588.	1.6	28
112	Ligand-Dependent Modulation of G Protein Conformation Alters Drug Efficacy. Cell, 2016, 167, 739-749.e11.	13.5	113
113	<scp>VCP</scp>746, a novel A₁ adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 976-982.	0.9	20
114	The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. Biochemical Pharmacology, 2016, 117, 46-56.	2.0	30
115	Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor. Biochemical Pharmacology, 2016, 118, 68-87.	2.0	41
116	Molecular Mechanisms of Action of M₅ Muscarinic Acetylcholine Receptor Allosteric Modulators. Molecular Pharmacology, 2016, 90, 427-436.	1.0	24
117	Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation. Cell, 2016, 166, 1084-1102.	13.5	246
118	The role of kinetic context in apparent biased agonism at GPCRs. Nature Communications, 2016, 7, 10842.	5.8	270
119	Positive Allosteric Modulation of the Muscarinic M₁Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 354-365.	1.3	21
120	Structure-Activity Analysis of Biased Agonism at the Human Adenosine A₃ Receptor. Molecular Pharmacology, 2016, 90, 12-22.	1.0	37
121	The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism. Cell, 2016, 165, 1632-1643.	13.5	126
122	Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. Biochemical Pharmacology, 2016, 113, 70-87.	2.0	48
123	Use of Cysteine Trapping to Map Spatial Approximations between Residues Contributing to the Helix N-capping Motif of Secretin and Distinct Residues within Each of the Extracellular Loops of Its Receptor. Journal of Biological Chemistry, 2016, 291, 5172-5184.	1.6	9
124	Novel Fused Arylpyrimidinone Based Allosteric Modulators of the M₁ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2016, 7, 647-661.	1.7	14
125	Prediction of Loops in G Protein-Coupled Receptor Homology Models: Effect of Imprecise Surroundings and Constraints. Journal of Chemical Information and Modeling, 2016, 56, 671-686.	2.5	7
126	Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. Cell Research, 2016, 26, 574-592.	5.7	85

#	Article	IF	Citations
127	Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 36-44.	1.3	50
128	Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors. ACS Chemical Biology, 2016, 11, 1220-1229.	1.6	63
129	Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature, 2016, 531, 335-340.	13.7	272
130	4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M₁ Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry, 2016, 59, 388-409.	2.9	35
131	A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures. Molecular Pharmacology, 2016, 89, 335-347.	1.0	56
132	Quantification of adenosine A 1 receptor biased agonism: Implications for drug discovery. Biochemical Pharmacology, 2016, 99, 101-112.	2.0	58
133	Microglial activation and progressive brain changes in schizophrenia. British Journal of Pharmacology, 2016, 173, 666-680.	2.7	185
134	M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. Journal of Clinical Investigation, 2016, 127, 487-499.	3.9	56
135	Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants. PLoS ONE, 2016, 11, e0146846.	1.1	42
136	Biased allosteric modulation at the <scp>CaS</scp> receptor engendered by structurally diverse calcimimetics. British Journal of Pharmacology, 2015, 172, 185-200.	2.7	71
137	Development of a Highly Selective Allosteric Antagonist Radioligand for the Type 1 Cholecystokinin Receptor and Elucidation of Its Molecular Basis of Binding. Molecular Pharmacology, 2015, 87, 130-140.	1.0	10
138	Receptor Expression Modulates Calcium-Sensing Receptor Mediated Intracellular Ca²⁺Mobilization. Endocrinology, 2015, 156, 1330-1342.	1.4	20
139	Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. Journal of Medicinal Chemistry, 2015, 58, 9562-9577.	2.9	15
140	Binding Pockets and Poses of Allosteric Modulators of Opioid Receptors Identified by Metadynamics. Biophysical Journal, 2015, 108, 415a.	0.2	0
141	Proof of Concept Study for Designed Multiple Ligands Targeting the Dopamine D₂, Serotonin 5-HT_{2A}, and Muscarinic M₁ Acetylcholine Receptors. Journal of Medicinal Chemistry, 2015, 58, 1550-1555.	2.9	14
142	Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias. Trends in Pharmacological Sciences, 2015, 36, 215-225.	4.0	41
143	Biased Agonism and Biased Allosteric Modulation at the CB₁ Cannabinoid Receptor. Molecular Pharmacology, 2015, 88, 368-379.	1.0	118
144	Structureâ€“Activity Study of N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a Bitopic Ligand That Acts as a Negative Allosteric Modulator of the Dopamine D₂ Receptor. Journal of Medicinal Chemistry, 2015, 58, 5287-5307.	2.9	40

#	Article	IF	Citations
145	Novel Allosteric Modulators of G Protein-coupled Receptors. Journal of Biological Chemistry, 2015, 290, 19478-19488.	1.6	173
146	Detection and Quantification of Allosteric Modulation of Endogenous M4 Muscarinic Acetylcholine Receptor Using Impedance-Based Label-Free Technology in a Neuronal Cell Line. Journal of Biomolecular Screening, 2015, 20, 646-654.	2.6	8
147	Synthesis and Pharmacological Evaluation of M₄ Muscarinic Receptor Positive Allosteric Modulators Derived from VU10004. ACS Chemical Neuroscience, 2015, 6, 838-844.	1.7	16
148	Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the Î´-Opioid Receptor. Journal of Medicinal Chemistry, 2015, 58, 4220-4229.	2.9	54
149	Differential Impact of Amino Acid Substitutions on Critical Residues of the Human Glucagon-Like Peptide-1 Receptor Involved in Peptide Activity and Small-Molecule Allostery. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 52-63.	1.3	18
150	Endogenous Allosteric Modulators of G Proteinâ€“Coupled Receptors. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 246-260.	1.3	127
151	A structureâ€“activity relationship study of the positive allosteric modulator LY2033298 at the M₄ muscarinic acetylcholine receptor. MedChemComm, 2015, 6, 1998-2003.	3.5	7
152	Biased Agonism of Endogenous Opioid Peptides at theÎ¼-Opioid Receptor. Molecular Pharmacology, 2015, 88, 335-346.	1.0	93
153	Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D₂ Receptor Through Fragmentation of a Bitopic Ligand. Journal of Medicinal Chemistry, 2015, 58, 6819-6843.	2.9	47
154	A Positive Allosteric Modulator of the Adenosine A₁ Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model. Molecular Pharmacology, 2015, 88, 460-468.	1.0	53
155	Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists. Molecular Pharmacology, 2015, 88, 779-790.	1.0	17
156	Novel <scp>GPCR</scp> paradigms at the Î¼â€opioid receptor. British Journal of Pharmacology, 2015, 172, 287-296.	2.7	53
157	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4614-4619.	3.3	92
158	Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1).. Journal of Biological Chemistry, 2014, 289, 13362.	1.6	4
159	Characterization of the Novel Positive Allosteric Modulator, LY2119620, at the Muscarinic M₂and M₄Receptors. Molecular Pharmacology, 2014, 86, 106-115.	1.0	42
160	Quantification of Ligand Bias for Clinically Relevant Î²₂-Adrenergic Receptor Ligands: Implications for Drug Taxonomy. Molecular Pharmacology, 2014, 85, 492-509.	1.0	207
161	Engendering biased signalling from the calciumâ€sensing receptor for the pharmacotherapy of diverse disorders. British Journal of Pharmacology, 2014, 171, 1142-1155.	2.7	37
162	Interview with Arthur Christopoulos. Trends in Pharmacological Sciences, 2014, 35, 624-627.	4.0	1

#	Article	IF	Citations
163	Allosteric Modulation of Chemokine Receptors. Topics in Medicinal Chemistry, 2014, , 87-117.	0.4	2
164	Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2014, 289, 33701-33711.	1.6	49
165	Molecular Mechanisms of Bitopic Ligand Engagement with the M1 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2014, 289, 23817-23837.	1.6	55
166	Functional and structural perspectives on allosteric modulation of GPCRs. Current Opinion in Cell Biology, 2014, 27, 94-101.	2.6	32
167	Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2014, 289, 6067-6079.	1.6	51
168	Allosteric targeting of receptor tyrosine kinases. Nature Biotechnology, 2014, 32, 1113-1120.	9.4	73
169	Structural Basis of Receptor Sulfotyrosine Recognition by a CC Chemokine: The N-Terminal Region of CCR3 Bound to CCL11/Eotaxin-1. Structure, 2014, 22, 1571-1581.	1.6	70
170	Advances in G Protein-Coupled Receptor Allostery: From Function to Structure. Molecular Pharmacology, 2014, 86, 463-478.	1.0	192
171	Roles of intraloopsâ€2 and â€3 and the proximal Câ€terminus in signalling pathway selection from the human calciumâ€sensing receptor. FEBS Letters, 2014, 588, 3340-3346.	1.3	13
172	Synthesis and Pharmacological Evaluation of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) Designed to Bind Irreversibly to an Allosteric Site of the M1Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry, 2014, 57, 5405-5418.	2.9	27
173	A new mechanism of allostery in a G proteinâ€“coupled receptor dimer. Nature Chemical Biology, 2014, 10, 745-752.	3.9	108
174	Biased Agonism at G Proteinâ€Coupled Receptors: The Promise and the Challengesâ€”A Medicinal Chemistry Perspective. Medicinal Research Reviews, 2014, 34, 1286-1330.	5.0	92
175	International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands. Pharmacological Reviews, 2014, 66, 918-947.	7.1	189
176	Structureâ€“Activity Relationships of Privileged Structures Lead to the Discovery of Novel Biased Ligands at the Dopamine D₂ Receptor. Journal of Medicinal Chemistry, 2014, 57, 4924-4939.	2.9	67
177	Allosteric Modulation of M1 Muscarinic Acetylcholine Receptor Internalization and Subcellular Trafficking. Journal of Biological Chemistry, 2014, 289, 15856-15866.	1.6	31
178	Development of a Photoactivatable Allosteric Ligand for the M₁ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2014, 5, 902-907.	1.7	9
179	Development of a Radioligand, [3H]LY2119620, to Probe the Human M2 and M4 Muscarinic Receptor Allosteric Binding Sites. Molecular Pharmacology, 2014, 86, 116-123.	1.0	25
180	Muscarinic acetylcholine receptors: novel opportunities for drug development. Nature Reviews Drug Discovery, 2014, 13, 549-560.	21.5	337

#	Article	IF	Citations
181	Prolonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias. PLoS ONE, 2014, 9, e92042.	1.1	60
182	Emerging paradigms in GPCR allostery: implications for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 630-644.	21.5	396
183	Molecular Basis for Benzodiazepine Agonist Action at the Type 1 Cholecystokinin Receptor. Journal of Biological Chemistry, 2013, 288, 21082-21095.	1.6	19
184	Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature, 2013, 503, 295-299.	13.7	365
185	A Structureâ€"Activity Analysis of Biased Agonism at the Dopamine D2 Receptor. Journal of Medicinal Chemistry, 2013, 56, 9199-9221.	2.9	80
186	Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature, 2013, 504, 101-106.	13.7	779
187	Probing Structural Requirements of Positive Allosteric Modulators of the M₄ Muscarinic Receptor. Journal of Medicinal Chemistry, 2013, 56, 8196-8200.	2.9	20
188	Reverse Engineering of the Selective Agonist TBPB Unveils Both Orthosteric and Allosteric Modes of Action at the M1 Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2013, 84, 425-437.	1.0	31
189	Allosteric Modulation of a Chemogenetically Modified G Protein-Coupled Receptor. Molecular Pharmacology, 2013, 83, 521-530.	1.0	24
190	Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. Biochemical Society Transactions, 2013, 41, 172-179.	1.6	59
191	Supraâ€physiological efficacy at <scp>GPCRs</scp>: superstition or super agonists?. British Journal of Pharmacology, 2013, 169, 353-356.	2.7	26
192	Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nature Reviews Drug Discovery, 2013, 12, 205-216.	21.5	627
193	Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends in Pharmacological Sciences, 2013, 34, 59-66.	4.0	150
194	Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties. Cancer Cell, 2013, 23, 477-488.	7.7	138
195	Synthesis and Pharmacological Profiling of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric Modulators of the M₁ Muscarinic Receptor. Journal of Medicinal Chemistry, 2013, 56, 5151-5172.	2.9	53
196	Development of M₁ mAChR Allosteric and Bitopic Ligands: Prospective Therapeutics for the Treatment of Cognitive Deficits. ACS Chemical Neuroscience, 2013, 4, 1026-1048.	1.7	58
197	Measurements of ligand bias and functional affinity. Nature Reviews Drug Discovery, 2013, 12, 483-483.	21.5	57
198	Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite. British Journal of Pharmacology, 2013, 169, 659-670.	2.7	21

#	Article	IF	Citations
199	Differential Activation and Modulation of the Glucagon-Like Peptide-1 Receptor by Small Molecule Ligands. Molecular Pharmacology, 2013, 83, 822-834.	1.0	77
200	Impact of Clinically Relevant Mutations on the Pharmacoregulation and Signaling Bias of the Calcium-Sensing Receptor by Positive and Negative Allosteric Modulators. Endocrinology, 2013, 154, 1105-1116.	1.4	68
201	Tyrosine Sulfation of Chemokine Receptor CCR2 Enhances Interactions with Both Monomeric and Dimeric Forms of the Chemokine Monocyte Chemoattractant Protein-1 (MCP-1). Journal of Biological Chemistry, 2013, 288, 10024-10034.	1.6	90
202	Minireview: Signal Bias, Allosterism, and Polymorphic Variation at the GLP-1R: Implications for Drug Discovery. Molecular Endocrinology, 2013, 27, 1234-1244.	3.7	30
203	Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5211-5216.	3.3	203
204	CGRP/Adrenomedullin. , 2013, , 744-751.		0
205	Calcium-sensing receptor-dependent activation of CREB phosphorylation in HEK293 cells and human parathyroid cells. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E1097-E1104.	1.8	24
206	A simple method to generate stable cell lines for the analysis of transient protein-protein interactions. BioTechniques, 2013, 54, 217-221.	0.8	16
207	Adenosine A1 Receptor Biased Agonism: A Novel Approach for Cardioprotective Therapeutics. FASEB Journal, 2013, 27, lb617.	0.2	0
208	Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects. Molecular Pharmacology, 2012, 81, 41-52.	1.0	115
209	Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18607-18612.	3.3	62
210	Stimulus Bias Provides Evidence for Conformational Constraints in the Structure of a G Protein-coupled Receptor. Journal of Biological Chemistry, 2012, 287, 37066-37077.	1.6	28
211	Identification of Molecular Phenotypes and Biased Signaling Induced by Naturally Occurring Mutations of the Human Calcium-Sensing Receptor. Endocrinology, 2012, 153, 4304-4316.	1.4	72
212	Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery. Journal of Medicinal Chemistry, 2012, 55, 1445-1464.	2.9	212
213	Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin. Molecular Pharmacology, 2012, 82, 1066-1073.	1.0	51
214	Synthesis and Characterization of Novel 2-Amino-3-benzoylthiophene Derivatives as Biased Allosteric Agonists and Modulators of the Adenosine A₁ Receptor. Journal of Medicinal Chemistry, 2012, 55, 2367-2375.	2.9	53
215	Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Differentially Regulates Orthosteric but Not Allosteric Agonist Binding and Function. Journal of Biological Chemistry, 2012, 287, 3659-3673.	1.6	30
216	Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Has a Critical Role in GLP-1 Peptide Binding and Receptor Activation. Journal of Biological Chemistry, 2012, 287, 3642-3658.	1.6	83

#	Article	IF	Citations
217	A Simple Method for Quantifying Functional Selectivity and Agonist Bias. ACS Chemical Neuroscience, 2012, 3, 193-203.	1.7	422
218	Consequences of splice variation on Secretin family G proteinâ€coupled receptor function. British Journal of Pharmacology, 2012, 166, 98-109.	2.7	44
219	Design and Receptor Interactions of Obligate Dimeric Mutant of Chemokine Monocyte Chemoattractant Protein-1 (MCP-1). Journal of Biological Chemistry, 2012, 287, 14692-14702.	1.6	43
220	Structureâ€"Function Studies of Muscarinic Acetylcholine Receptors. Handbook of Experimental Pharmacology, 2012, , 29-48.	0.9	16
221	The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Proteinâ€"Coupled Receptors. Annual Review of Pharmacology and Toxicology, 2012, 52, 153-178.	4.2	148
222	Positive and Negative Allosteric Modulators Promote Biased Signaling at the Calcium-Sensing Receptor. Endocrinology, 2012, 153, 1232-1241.	1.4	142
223	A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation. Journal of Biological Chemistry, 2012, 287, 650-659.	1.6	98
224	Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery. Molecular Pharmacology, 2012, 82, 281-290.	1.0	69
225	RAMPs as Drug Targets. Advances in Experimental Medicine and Biology, 2012, 744, 61-74.	0.8	10
226	Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6-tetrahydropyridines as 5-HT2C agonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2560-2564.	1.0	7
227	Modulation of the Glucagon-Like Peptide-1 Receptor Signaling by Naturally Occurring and Synthetic Flavonoids. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 540-550.	1.3	67
228	Polymorphism and Ligand Dependent Changes in Human Glucagon-Like Peptide-1 Receptor (GLP-1R) Function: Allosteric Rescue of Loss of Function Mutation. Molecular Pharmacology, 2011, 80, 486-497.	1.0	84
229	Quantification of Functional Selectivity at the Human Î±_{1A}-Adrenoceptor. Molecular Pharmacology, 2011, 79, 298-307.	1.0	69
230	Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opinion on Drug Discovery, 2011, 6, 811-825.	2.5	64
231	Analytical pharmacology: the impact of numbers on pharmacology. Trends in Pharmacological Sciences, 2011, 32, 189-196.	4.0	33
232	Allosteric modulation of G protein-coupled receptors: A pharmacological perspective. Neuropharmacology, 2011, 60, 24-35.	2.0	235
233	Application of an Allosteric Ternary Complex Model to the Technique of Pharmacological Resultant Analysis. Journal of Pharmacy and Pharmacology, 2011, 49, 781-786.	1.2	17
234	Impact of species variability and â€˜probeâ€dependenceâ€™ on the detection andin vivovalidation of allosteric modulation at the M₄muscarinic acetylcholine receptor. British Journal of Pharmacology, 2011, 162, 1659-1670.	2.7	60

#	Article	IF	Citations
235	Allostery in GPCRs: â€˜MWCâ€™ revisited. Trends in Biochemical Sciences, 2011, 36, 663-672.	3.7	64
236	The synthesis and biological evaluation of 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophenes as allosteric modulators of the A1 adenosine receptor. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3704-3707.	1.0	26
237	Quantification of Allosteric Interactions at G Proteinâ€“Coupled Receptors Using Radioligand Binding Assays. Current Protocols in Pharmacology, 2011, 52, Unit 1.22.	4.0	13
238	The Role of Transmembrane Domain 3 in the Actions of Orthosteric, Allosteric, and Atypical Agonists of the M₄Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2011, 79, 855-865.	1.0	32
239	Allosteric Modulation of the Calcium-sensing Receptor by Î³-Glutamyl Peptides. Journal of Biological Chemistry, 2011, 286, 8786-8797.	1.6	82
240	Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clinical Science, 2011, 121, 297-303.	1.8	241
241	The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. Brain Research, 2010, 1343, 153-167.	1.1	50
242	H2 Relaxin Is a Biased Ligand Relative to H3 Relaxin at the Relaxin Family Peptide Receptor 3 (RXFP3). Molecular Pharmacology, 2010, 77, 759-772.	1.0	33
243	Prediction of Functionally Selective Allosteric Interactions at an M₃Muscarinic Acetylcholine Receptor Mutant Using Saccharomyces cerevisiae. Molecular Pharmacology, 2010, 78, 205-214.	1.0	19
244	Delineating the Mode of Action of Adenosine A₁ Receptor Allosteric Modulators. Molecular Pharmacology, 2010, 78, 444-455.	1.0	39
245	Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M₁Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2010, 78, 94-104.	1.0	61
246	Receptor Activity Modifying Proteins and Their Potential as Drug Targets. Progress in Molecular Biology and Translational Science, 2010, 91, 53-79.	0.9	11
247	Effects of Conformational Restriction of 2-Amino-3-benzoylthiophenes on A₁ Adenosine Receptor Modulation. Journal of Medicinal Chemistry, 2010, 53, 6550-6559.	2.9	31
248	Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening. Molecular Pharmacology, 2010, 78, 456-465.	1.0	195
249	Detection of Novel Functional Selectivity at M₃ Muscarinic Acetylcholine Receptors Using a Saccharomyces cerevisiae Platform. ACS Chemical Biology, 2010, 5, 365-375.	1.6	24
250	Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias. Journal of Biological Chemistry, 2010, 285, 7459-7474.	1.6	149
251	Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties. Neuropsychopharmacology, 2010, 35, 855-869.	2.8	143
252	Overview of Receptor Allosterism. Current Protocols in Pharmacology, 2010, 51, Unit 1.21.	4.0	34

#	Article	IF	Citations
253	Structural Determinants of Allosteric Agonism and Modulation at the M4 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2010, 285, 19012-19021.	1.6	70
254	Understanding Amylin Receptors. , 2010, , 41-57.		3
255	Effect of the Calcimimetic R-568 [3-(2-Chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on Correcting Inactivating Mutations in the Human Calcium-Sensing Receptor. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 775-786.	1.3	40
256	Functional Importance of a Structurally Distinct Homodimeric Complex of the Family B G Protein-Coupled Secretin Receptor. Molecular Pharmacology, 2009, 76, 264-274.	1.0	49
257	Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB Journal, 2009, 23, 442-450.	0.2	140
258	Determination of Adenosine A₁Receptor Agonist and Antagonist Pharmacology UsingSaccharomyces cerevisiae: Implications for Ligand Screening and Functional Selectivity. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 277-286.	1.3	46
259	Comparison of Receptor Binding Characteristics of Commonly Used Muscarinic Antagonists in Human Bladder Detrusor and Mucosa. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 893-899.	1.3	43
260	Modulating receptor function through RAMPs: can they represent drug targets in themselves?. Drug Discovery Today, 2009, 14, 413-419.	3.2	55
261	Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Reviews Drug Discovery, 2009, 8, 41-54.	21.5	929
262	3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. Bioorganic and Medicinal Chemistry, 2009, 17, 7353-7361.	1.4	41
263	Allosteric Modulators of the Adenosine A₁ Receptor: Synthesis and Pharmacological Evaluation of 4-Substituted 2-Amino-3-benzoylthiophenes. Journal of Medicinal Chemistry, 2009, 52, 4543-4547.	2.9	124
264	Orthosteric/Allosteric Bitopic Ligands: Going Hybrid at GPCRs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2009, 9, 125-135.	3.4	81
265	Homology Modeling of GPCRs. Methods in Molecular Biology, 2009, 552, 97-113.	0.4	9
266	Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: Novel agonists for the CB1 receptor. European Journal of Medicinal Chemistry, 2008, 43, 513-539.	2.6	18
267	Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4401-4404.	1.0	27
268	Pharmacology of 5HT2C receptor-mediated ERK1/2 phosphorylation: Agonist-specific activation pathways and the impact of RNA editing. Biochemical Pharmacology, 2008, 76, 1276-1287.	2.0	19
269	RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. , 2008, 119, 7-23.		149
270	Synthesis and Cannabinoid Activity of a Variety of 2,3-Substituted 1-Benzo[b]thiophen Derivatives and 2,3-Substituted Benzofuran: Novel Agonists for the CB1 Receptor. Australian Journal of Chemistry, 2008, 61, 484.	0.5	6

#	Article	IF	Citations
271	The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors. Regulatory Peptides, 2008, 145, 65-71.	1.9	14
272	2-Aminothienopyridazines as Novel Adenosine A1 Receptor Allosteric Modulators and Antagonists. Journal of Medicinal Chemistry, 2008, 51, 6165-6172.	2.9	54
273	New Insights into the Function of M₄ Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	1
274	Receptor Activity-Modifying Proteins Differentially Modulate the G Protein-Coupling Efficiency of Amylin Receptors. Endocrinology, 2008, 149, 5423-5431.	1.4	130
275	Allosteric modulation of the muscarinic M ₄ receptor as an approach to treating schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10978-10983.	3.3	214
276	Identification of N-Terminal Receptor Activity-Modifying Protein Residues Important for Calcitonin Gene-Related Peptide, Adrenomedullin, and Amylin Receptor Function. Molecular Pharmacology, 2008, 74, 1059-1071.	1.0	69
277	A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity. Journal of Biological Chemistry, 2008, 283, 29312-29321.	1.6	165
278	The Impact of Orthosteric Radioligand Depletion on the Quantification of Allosteric Modulator Interactions. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 927-934.	1.3	11
279	Procalcitonin has bioactivity at calcitonin receptor family complexes: Potential mediator implications in sepsis*. Critical Care Medicine, 2008, 36, 1637-1640.	0.4	85
280	Characterisation of the adenosine A1 receptor in Saccharomyces cerevisiae. FASEB Journal, 2008, 22, 727.2.	0.2	0
281	Binding and functional characterisation of allosteric agonists at M2 muscarinic acetylcholine receptors. FASEB Journal, 2008, 22, 724.6.	0.2	0
282	Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands. Journal of Biological Chemistry, 2007, 282, 25677-25686.	1.6	137
283	Allosteric Modulation of Muscarinic Acetylcholine Receptors. Current Neuropharmacology, 2007, 5, 157-167.	1.4	114
284	Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11927-11932.	3.3	97
285	Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends in Pharmacological Sciences, 2007, 28, 382-389.	4.0	330
286	Functional Selectivity and Classical Concepts of Quantitative Pharmacology. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1-13.	1.3	997
287	Allosteric Modulation of G Proteinâ€“Coupled Receptors. Annual Review of Pharmacology and Toxicology, 2007, 47, 1-51.	4.2	615
288	Muscarinic Acetylcholine Receptors in the Central Nervous System: Structure, Function, and Pharmacology. , 2007, , 163-208.		3

#	Article	IF	Citations
289	Structure-Function Studies of Allosteric Agonism at M2Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2007, 72, 463-476.	1.0	105
290	Involvement of the sigma₁ (Ïƒ₁) receptor in the antiâ€amnesic, but not antidepressantâ€like, effects of the aminotetrahydrofuran derivative ANAVEX1â€41. British Journal of Pharmacology, 2007, 152, 267-279.	2.7	24
291	Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist. Molecular Pharmacology, 2006, 69, 236-246.	1.0	101
292	Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends in Pharmacological Sciences, 2006, 27, 475-481.	4.0	112
293	Complexing Receptor Pharmacology: Modulation of Family B G Protein-Coupled Receptor Function by RAMPs. Annals of the New York Academy of Sciences, 2006, 1070, 90-104.	1.8	72
294	Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors. Current Pharmaceutical Design, 2006, 12, 1683-1702.	0.9	36
295	Editorial [Hot Topic: G Protein-Coupled Receptor Drug Targets (Executive Editors: P.M. Sexton and A.) Tj ETQq1 1 0.784314 rgBT /Ove	0.9	0
296	A Critical Role for the Short Intracellular C Terminus in Receptor Activity-Modifying Protein Function. Molecular Pharmacology, 2006, 70, 1750-1760.	1.0	41
297	Distinct Receptor Activity-Modifying Protein Domains Differentially Modulate Interaction with Calcitonin Receptors. Molecular Pharmacology, 2006, 69, 1984-1989.	1.0	56
298	Determinants of 1-Piperidinecarboxamide, N-[2-[[5-Amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihyd (BIBN4096BS) Affinity for Calcitonin Gene-Related Peptide and Amylin Receptorsâ€"The Role of Receptor Activity Modifying Protein 1. Molecular Pharmacology, 2006, 70, 1984-1991.	1.0	88
299	Interaction Studies of Multiple Binding Sites on M4 Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2006, 70, 736-746.	1.0	26
300	On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2. Molecular Pharmacology, 2006, 69, 1441-1453.	1.0	48
301	Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. Journal of Neurochemistry, 2005, 93, 1603-1615.	2.1	85
302	Effects of urea pretreatment on the binding properties of adenosine A1 receptors. British Journal of Pharmacology, 2005, 146, 1119-1129.	2.7	11
303	Editorial [Hot Topic: Allosteric Modulators of G Protein-Coupled Receptors (Executive Editor: Arthur) Tj ETQq1 1 0.784314 rgBT /Over	1.1	0
304	Allosteric Modulation of the Cannabinoid CB1 Receptor. Molecular Pharmacology, 2005, 68, 1484-1495.	1.0	409
305	Regulation of M2 Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 382-390.	1.3	31
306	G-Proteinâ€"Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor. Circulation, 2005, 111, 1806-1813.	1.6	346

#	Article	IF	Citations
307	Evidence for Pleiotropic Signaling at the Mouse Î²3-Adrenoceptor Revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol Oxalate]. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1064-1074.	1.3	38
308	Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes. Molecular Pharmacology, 2005, 67, 1655-1665.	1.0	196
309	â€˜Ins and outsâ€™ of seven-transmembrane receptor signalling to ERK. Trends in Endocrinology and Metabolism, 2005, 16, 26-33.	3.1	86
310	Allosteric Modulation of G Protein-Coupled Receptors. Current Pharmaceutical Design, 2004, 10, 2003-2013.	0.9	84
311	Investigation of the Interaction of a Putative Allosteric Modulator, N-(2,3-Diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) Methanamine Hydrobromide (SCH-202676), with M1 Muscarinic Acetylcholine Receptors. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 830-837.	1.3	47
312	Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1062-1072.	1.3	52
313	The state of GPCR research in 2004. Nature Reviews Drug Discovery, 2004, 3, 577-626.	21.5	81
314	Regulation of serotonin 5-HT2C receptors by chronic ligand exposure. European Journal of Pharmacology, 2004, 498, 59-69.	1.7	17
315	Effects of anandamide on the binding and signaling properties of M1 muscarinic acetylcholine receptors. Biochemical Pharmacology, 2004, 68, 2207-2219.	2.0	21
316	Amylin receptors: molecular composition and pharmacology. Biochemical Society Transactions, 2004, 32, 865-867.	1.6	78
317	G-protein-coupled receptor allosterism: the promise and the problem(s). Biochemical Society Transactions, 2004, 32, 873-877.	1.6	53
318	International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. Pharmacological Reviews, 2003, 55, 597-606.	7.1	536
319	RAMPs: 5 years on, where to now?. Trends in Pharmacological Sciences, 2003, 24, 596-601.	4.0	83
320	Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences, 2003, 24, 580-588.	4.0	374
321	Allosteric modulators of G-protein-coupled receptors. Current Opinion in Pharmacology, 2003, 3, 551-556.	1.7	72
322	Novel Receptor Partners and Function of Receptor Activity-modifying Proteins. Journal of Biological Chemistry, 2003, 278, 3293-3297.	1.6	283
323	Cellular Signaling Mechanisms for Muscarinic Acetylcholine Receptors. Receptors and Channels, 2003, 9, 241-260.	1.1	88
324	Reversible and Specific Extracellular Antagonism of Receptor-Histidine Kinase Signaling. Journal of Biological Chemistry, 2002, 277, 6247-6253.	1.6	81

#	Article	IF	Citations
325	G Protein-Coupled Receptor Allosterism and Complexing. Pharmacological Reviews, 2002, 54, 323-374.	7.1	833
326	Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. Journal of Neurochemistry, 2002, 80, 1095-1102.	2.1	46
327	Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Reviews Drug Discovery, 2002, 1, 198-210.	21.5	574
328	Non-surmountable antagonism: transcending steady state. Trends in Pharmacological Sciences, 2001, 22, 65-66.	4.0	5
329	Insurmountable AT1 receptor antagonism: message in a model?. Trends in Pharmacological Sciences, 2001, 22, 555-557.	4.0	6
330	Annual Scientific Meeting of ASCEPT, 1999 From 'Captive' Agonism To Insurmountable Antagonism: Demonstrating The Power Of Analytical Pharmacology. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 223-229.	0.9	6
331	Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. British Journal of Pharmacology, 2001, 132, 1281-1291.	2.7	38
332	Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors. Brain Research, 2001, 915, 70-78.	1.1	40
333	The allosteric interaction of otenzepad (AF-DX 116) at muscarinic M2 receptors in guinea pig atria. European Journal of Pharmacology, 2001, 416, 235-244.	1.7	8
334	Transducer abstraction. Journal of Pharmacological and Toxicological Methods, 2000, 43, 55-67.	0.3	6
335	Further evidence for the heterogeneity of functional muscarinic receptors in guinea pig gallbladder. European Journal of Pharmacology, 2000, 388, 115-123.	1.7	9
336	Overview of Receptor Allosterism. Current Protocols in Pharmacology, 2000, 11, 1.21.1.	4.0	2
337	Beyond Eyeballing: Fitting Models to Experimental Data. Critical Reviews in Biochemistry and Molecular Biology, 2000, 35, 359-391.	2.3	34
338	Quantification of Allosteric Interactions at G Protein Coupled Receptors Using Radioligand Binding Assays. Current Protocols in Pharmacology, 2000, 11, 1.22.1.	4.0	12
339	Dynamic mechanisms of non-classical antagonism by competitive AT1 receptor antagonists. Trends in Pharmacological Sciences, 2000, 21, 376-381.	4.0	38
340	Characterization of the subtype selectivity of the allosteric modulator heptane-1,7-bis-(dimethyl-3â€²-phthalimidopropyl) ammonium bromide (c7/3-phth) at cloned muscarinic acetylcholine receptors. Biochemical Pharmacology, 1999, 57, 171-179.	2.0	33
341	Qualitative and quantitative assessment of relative agonist efficacy. Biochemical Pharmacology, 1999, 58, 735-748.	2.0	46
342	Regulation of acetylcholine binding by ATP at the muscarinic M1 receptor in intact CHO cells. Brain Research, 1999, 839, 94-99.	1.1	5

#	Article	IF	Citations
343	The assessment of antagonist potency under conditions of transient response kinetics. European Journal of Pharmacology, 1999, 382, 217-227.	1.7	58
344	ALLOSTERIC INTERACTIONS AT MUSCARINIC CHOLINOCEPTORS. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 185-194.	0.9	96
345	Use of a spreadsheet to quantitate the equilibrium binding of an allosteric modulator. European Journal of Pharmacology, 1998, 355, 103-111.	1.7	5
346	Assessing the distribution of parameters in models of ligandâ€“receptor interaction: to log or not to log. Trends in Pharmacological Sciences, 1998, 19, 351-357.	4.0	168
347	The generation of nitric oxide by G protein-coupled receptors. Life Sciences, 1998, 64, 1-15.	2.0	45
348	Novel persistent activation of muscarinic M1 receptors by xanomeline. European Journal of Pharmacology, 1997, 334, R3-R4.	1.7	15
349	Pharmacological analysis of the mode of interaction of McN-A-343 at atrial muscarinic M2 receptors. European Journal of Pharmacology, 1997, 339, 153-156.	1.7	16
350	Kinetic studies of co-operativity at atrial muscarinic m2 receptors with an â€œinfinite dilutionâ€• procedure. Biochemical Pharmacology, 1997, 53, 795-800.	2.0	26
351	Interactions of agonists with an allosteric antagonist at muscarinic acetylcholine M2 receptors. European Journal of Pharmacology, 1996, 316, 27-32.	1.7	26
352	[3H]N-methylscopolamine dissociation from muscarine receptors affected by low concentrations of allosteric modulators. European Journal of Pharmacology, 1995, 290, 259-262.	2.7	6
353	Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-3â€²-phthalimidopropyl) ammonium bromide at cholinoceptor sites. European Journal of Pharmacology, 1993, 246, 1-8.	2.7	14
354	Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-3â€²-phthalimidopropyl) ammonium bromide at cholinoceptor sites. European Journal of Pharmacology, 1993, 247, 227.	2.7	0
355	Second Messenger Assays for G Protein-Coupled Receptors: cAMP, Ca2+, Inositol Phosphates, ERK1/2. , 0, , 31-52.		0
356	Examining the Role of the Linker in Bitopic N⁶-Substituted Adenosine Derivatives Acting as Biased Adenosine A₁ Receptor Agonists. Journal of Medicinal Chemistry, 0, , .	2.9	1